TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18237622

Group type: EXPERIMENTAL
Intervention: Adoption of CONSORT in Nursing Research journal
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quality of reporting in RCTs across 4 nursing journals
Number of subjects: 100
Study: 16752669

Group type: EXPERIMENTAL
Intervention: Intravaginal Misoprostol (50 microg)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Transcervical Foley catheter (size 16F)
Number of subjects: 198
Study: 14504162

Group type: COMPARATOR
Intervention: Propofol-pronounced anaesthesia (propofol 100 microg x kg(‐1) min(‐1); remifentanil 0.15 microg x kg(‐1) min(‐1))
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Remifentanil-pronounced anaesthesia (propofol 50 microg x kg(‐1) min(‐1); remifentanil 0.45 microg x kg(‐1) min(‐1))
Number of subjects: 100
Study: 10096971

Group type: EXPERIMENTAL
Intervention: Synthetic, absorbable sealant
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard closure without sealant
Number of subjects: 26
Study: 8947088

Group type: EXPERIMENTAL
Intervention: Alcohol (1.5 mL x kg(‐1) body weight vodka, 40% alcohol by volume)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CPAP (ResCare AutoSet)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CPAP with Alcohol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alcohol (without CPAP)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 14
Study: 1912129

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7039644

Group type: EXPERIMENTAL
Intervention: Extradural analgesia and vagal blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30657782

Group type: EXPERIMENTAL
Intervention: e-learning course on patient safety (ELPAS)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Control group (no didactic session on patient safety)
Number of subjects: 463
Study: 30509367

Group type: EXPERIMENTAL
Intervention: Adrenaline 1:250,000
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Adrenaline 1:500,000
Number of subjects: 11

Group type: COMPARATOR
Intervention: No adrenaline
Number of subjects: 11
Study: 28778218

Group type: EXPERIMENTAL
Intervention: Matched treatment (MT) aimed specifically at hip strengthening
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 24
Study: 25330452

Group type: EXPERIMENTAL
Intervention: EX-FIB I (exercise designed to reduce glycogen of type I muscle fibers)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: EX-FIB II (exercise designed to reduce glycogen of type II muscle fibers)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CONT (4-km TT without prior exercise)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: EX-FIB I
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: EX-FIB II
Number of subjects: 10
Study: 24341531

Group type: EXPERIMENTAL
Intervention: ABI <0.9 (Peripheral Arterial Disease - PAD)
Number of subjects: 3307

Group type: EXPERIMENTAL
Intervention: ABI ≥1.4 (Arterial Calcification - AC)
Number of subjects: 3307

Group type: COMPARATOR
Intervention: ABI 0.9-1.4 (Healthy)
Number of subjects: 3307
Study: 20687927

Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI) measurement
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Investigator and patient questionnaires
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: ABI values at rest
Number of subjects: 1000
Study: 19041041

Group type: EXPERIMENTAL
Intervention: Pulsed arterial spin labeling (PASL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: H(2)(15)O PET
Number of subjects: 10
Study: 16639345

Group type: EXPERIMENTAL
Intervention: 25 mg once daily of maraviroc
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 300 mg twice daily of maraviroc
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 12665537

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 46
Study: 10953403

Group type: EXPERIMENTAL
Intervention: Direct access referrals
Number of subjects: 721

Group type: COMPARATOR
Intervention: Standard letter referrals
Number of subjects: 721
Study: 8858671

Group type: EXPERIMENTAL
Intervention: Amoxicillin (50 mg/kg/day divided twice daily) for 6 days
Number of subjects: 321

Group type: COMPARATOR
Intervention: Penicillin V (45 mg/kg/day divided into three doses/day) for 10 days
Number of subjects: 321
Study: 8389688

Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 11
Study: 3494548

Group type: EXPERIMENTAL
Intervention: Ultrafast cardiac computed tomography (CT)
Number of subjects: 25
Study: 29855294

Group type: EXPERIMENTAL
Intervention: Simultaneous treatment
Number of subjects: 2540

Group type: EXPERIMENTAL
Intervention: Sequential treatment
Number of subjects: 2540

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 2540
Study: 26913614

Group type: EXPERIMENTAL
Intervention: Strongest Families Smart Website (SFSW) intervention group
Number of subjects: 464

Group type: COMPARATOR
Intervention: Education control group
Number of subjects: 464
Study: 24581924

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Primary study objective (death, MI, or CVA)
Number of subjects: 817

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 817
Study: 22337679

Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 μg/d)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 19748617

Group type: EXPERIMENTAL
Intervention: New incentive system for pressure ulcer management introduced in 39 institutions.
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (20 non-introduced institutions).
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: New incentive system for pressure ulcer management.
Number of subjects: 105
Study: 17431604

Group type: COMPARATOR
Intervention: 0 mmole oxalate load
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 mmole oxalate load
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 mmole oxalate load
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 8 mmole oxalate load
Number of subjects: 12
Study: 15756419

Group type: EXPERIMENTAL
Intervention: LEF-1 expression in carcinoma samples
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: LEF-1 expression in brain cancer samples
Number of subjects: 360

Group type: COMPARATOR
Intervention: LEF-1 expression in testicular tumor samples
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: LEF-1 expression in lymphocytic leukemias
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: LEF-1 expression in acute myeloid leukemia and acute lymphocytic leukemia
Number of subjects: 360
Study: 11886736

Group type: EXPERIMENTAL
Intervention: Scooting
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional running
Number of subjects: 24
Study: 10448286

Group type: EXPERIMENTAL
Intervention: 5-FU/LV plus IFN-alpha-2c (30 micrograms subcutaneously, three times weekly)
Number of subjects: 269

Group type: COMPARATOR
Intervention: 5-FU/LV (100 mg/m2 intravenously followed by 5-FU, 500 mg/m2 as a 1-h i.v. infusion, daily for 4 days)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 5-FU/LV plus IFN-alpha-2c
Number of subjects: 269

Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 269
Study: 8880671

Group type: EXPERIMENTAL
Intervention: Clean and Sober Unit (experimental group)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Unaffiliated shelters (control group)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Domiciled men (control group)
Number of subjects: 189
Study: 1521303

Group type: EXPERIMENTAL
Intervention: Chewing gum sweetened with sorbitol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chewing gum sweetened with sorbitol/xylitol (3:1)
Number of subjects: 0
Study: 6240755

Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase (n = 7)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard therapy (n = 32)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PTCR (n = 2 matched patients)
Number of subjects: 42
Study: 31647177

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (natural healing)
Number of subjects: 33
Study: 29558208

Group type: EXPERIMENTAL
Intervention: Sectioning of the ALL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sectioning of the Kaplan fibers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sectioning of the ACL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sectioning of the ALL and Kaplan fibers
Number of subjects: 20
Study: 27505684

Group type: EXPERIMENTAL
Intervention: 1,064 nm long‐pulse Nd:YAG laser treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control scar (contralateral scar)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Masked examination of photographs
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Side effects reported by subjects and graders
Number of subjects: 9
Study: 25369399

Group type: EXPERIMENTAL
Intervention: Group D (chewed gum >3 hours at a time)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Group C (chewed gum 3 hours/day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Group A (chewed gum <1 hour/day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Group B (chewed gum 1-2 hours/day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Group E (chewed gum 1-3 times/week for at least 1 hour each occurrence)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Group F (didn't chew gum but had other parafunctional oral habits)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Group G (didn't have parafunctional oral habits)
Number of subjects: 51
Study: 22826271

Group type: EXPERIMENTAL
Intervention: Six cycles of doxorubicin/cyclophosphamide (AC) or Paclitaxel (T)
Number of subjects: 3171

Group type: COMPARATOR
Intervention: Four cycles of doxorubicin/cyclophosphamide (AC) or Paclitaxel (T)
Number of subjects: 3171
Study: 20332605

Group type: EXPERIMENTAL
Intervention: Single dose of 100 mg epirubicin instillation within 6 hours after TUR-BT
Number of subjects: 299

Group type: COMPARATOR
Intervention: Double dose of 100 mg epirubicin instillation (second dose during 12th-18th hours after TUR-BT)
Number of subjects: 299
Study: 17599428

Group type: EXPERIMENTAL
Intervention: Intensive glycemia treatment arm of the ACCORD trial
Number of subjects: 0
Study: 16301244

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Balanced anesthesia (BAL)
Number of subjects: 43
Study: 11981389

Group type: EXPERIMENTAL
Intervention: Cochlear Implantation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hearing Aids
Number of subjects: 20
Study: 9862290

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 7631894

Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg/day
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1735399

Group type: EXPERIMENTAL
Intervention: 6.7 ml of 0.75% bupivacaine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 17
Study: 6367832

Group type: EXPERIMENTAL
Intervention: EMG-assisted relaxation training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 31104357

Group type: EXPERIMENTAL
Intervention: Microinjections of human neural stem cells (hNSCs) into the spinal cord
Number of subjects: 18
Study: 29972759

Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg once daily)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 707
Study: 25673181

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 465
Study: 24382782

Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 (rIL-2) treatment for 90 days, including six courses of low-dose daily rIL-2 followed by 3-day high-dose boluses.
Number of subjects: 214

Group type: COMPARATOR
Intervention: Observation (no further therapy).
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 (rIL-2) treatment for 90 days.
Number of subjects: 214
Study: 21993078

Group type: EXPERIMENTAL
Intervention: arzoxifene 20 mg/d
Number of subjects: 9354

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9354
Study: 19018977

Group type: EXPERIMENTAL
Intervention: Atropine 0.5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17959989

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA) with propofol, nitrous oxide/sevoflurane, and fentanyl
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA) with bupivacaine hydrochloride
Number of subjects: 40
Study: 15846259

Group type: EXPERIMENTAL
Intervention: Clopidogrel added to standard fibrinolytic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard fibrinolytic therapy alone (placebo control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study: 12217154

Group type: EXPERIMENTAL
Intervention: Videoconferencing as an alternative to general practitioner referral to a hospital specialist
Number of subjects: 3170

Group type: COMPARATOR
Intervention: General practitioner referral to a hospital specialist
Number of subjects: 3170
Study: 9708644

Group type: COMPARATOR
Intervention: CE (Cyclophosphamide 4 g/m2, Etoposide 600 mg/m2, G‐CSF 6 microg/kg/day)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: CEP (Cyclophosphamide 4 g/m2, Etoposide 600 mg/m2, G‐CSF 6 microg/kg/day, Cisplatin 105 mg/m2)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: CEP
Number of subjects: 81

Group type: COMPARATOR
Intervention: CE and CEP
Number of subjects: 81
Study: 7893440

Group type: EXPERIMENTAL
Intervention: Retrovector-transduced autologous fibroblasts (VTAF) administered via three intramuscular injections at 2-week intervals.
Number of subjects: 4
Study: 2712548

Group type: COMPARATOR
Intervention: Norfloxacin, 400 mg alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sucralfate, 1 g concurrently with norfloxacin, 400 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sucralfate, 1 g followed by norfloxacin, 400 mg, 2 h later
Number of subjects: 8
Study: 996785

Group type: EXPERIMENTAL
Intervention: Zeta potential reduction test in cystic fibrosis genotypes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normal individuals)
Number of subjects: 0
Study: 31989232

Group type: EXPERIMENTAL
Intervention: Liposuction with periareolar excision (delivery technique)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Liposuction with pull-through technique
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 20
Study: 30540337

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 21768

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21768

Group type: COMPARATOR
Intervention: Evolocumab vs Placebo
Number of subjects: 21768
Study: 26923543

Group type: EXPERIMENTAL
Intervention: Perturbation and plyometric training (PPT)
Number of subjects: 24
Study: 26061330

Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus S‐1 and cisplatin (NCS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: S‐1 and cisplatin (CS) alone
Number of subjects: 62
Study: 23273358

Group type: EXPERIMENTAL
Intervention: MI Paste Plus
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: PreviDent fluoride varnish
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual home care (control)
Number of subjects: 115
Study: 21451365

Group type: EXPERIMENTAL
Intervention: Immunohistochemical analysis using a resource-saving diagnostic staining panel for precursor cell neoplasms.
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: World Health Organization guidelines for lineage determination and subtyping of precursor cell leukemia.
Number of subjects: 193
Study: 18789762

Group type: EXPERIMENTAL
Intervention: Low-GI (LGI) meal (GI=36)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-GI (HGI) meal (GI=83)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (CON) (low energy sugar-free jelly)
Number of subjects: 8
Study: 16829485

Group type: EXPERIMENTAL
Intervention: Full attention during picture study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Divided attention during picture study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mutual exclusivity instructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: No mutual exclusivity instructions
Number of subjects: 0
Study: 15231443

Group type: EXPERIMENTAL
Intervention: MDD with comorbid anxiety disorders (n = 18)
Number of subjects: 48

Group type: COMPARATOR
Intervention: All depressed patients (n = 33)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pure mood disorders (n = 15)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pure anxiety disorders (n = 15)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All patient groups
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cortisol response
Number of subjects: 48
Study: 11199952

Group type: EXPERIMENTAL
Intervention: Methadone patients
Number of subjects: 18

Group type: COMPARATOR
Intervention: Drug-free healthy controls
Number of subjects: 18
Study: 9017356

Group type: EXPERIMENTAL
Intervention: Inhaled insulin (99 U microcrystalline solid insulin)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Subcutaneous insulin (10 U regular insulin)
Number of subjects: 11
Study: 8313397

Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Brofaromine (150 mg/day)
Number of subjects: 220
Study: 3791560

Group type: COMPARATOR
Intervention: Single bolus injection of 300 mg/m2 (S arm)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Injection of 80 mg/m2 daily for 5 days (D x 5 arm)
Number of subjects: 72
Study: 31332902

Group type: EXPERIMENTAL
Intervention: Levomilnacipran (LVM)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 29654011

Group type: EXPERIMENTAL
Intervention: Multimorbidity Treatment Burden Questionnaire (MTBQ)
Number of subjects: 1546
Study: 27054932

Group type: EXPERIMENTAL
Intervention: Treatment for mild GDM diagnosed using Carpenter-Coustan criteria
Number of subjects: 958

Group type: COMPARATOR
Intervention: Untreated women
Number of subjects: 958
Study: 24788850

Group type: EXPERIMENTAL
Intervention: Workplace interventions
Number of subjects: 36
Study: 23771007

Group type: EXPERIMENTAL
Intervention: Three-point-touch fitting approach
Number of subjects: 61

Group type: COMPARATOR
Intervention: Apical touch fitting approach
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nipple cones
Number of subjects: 61

Group type: COMPARATOR
Intervention: Oval cones
Number of subjects: 61
Study: 20978374

Group type: EXPERIMENTAL
Intervention: MRK adenovirus type 5 gag/pol/nef HIV vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18405162

Group type: EXPERIMENTAL
Intervention: Acupuncture (blood-letting puncture and cupping at Ashi points)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 399
Study: 15641767

Group type: EXPERIMENTAL
Intervention: Gene-based vaccines (plasmid DNA and recombinant adenoviral vector carrying human PSMA)
Number of subjects: 0
Study: 12870340

Group type: EXPERIMENTAL
Intervention: Trabeculectomy combined with Mitomycin C and removed suture
Number of subjects: 75

Group type: COMPARATOR
Intervention: Normal trabeculectomy (Control)
Number of subjects: 75
Study: 10484239

Group type: EXPERIMENTAL
Intervention: Lipid-regulating treatment
Number of subjects: 21100000

Group type: COMPARATOR
Intervention: NCEP guidelines
Number of subjects: 21100000

Group type: COMPARATOR
Intervention: Cholesterol-lowering drug therapy
Number of subjects: 21100000
Study: 8698614

Group type: EXPERIMENTAL
Intervention: Double-blinded capsules containing different levels of vitamin C and beta-carotene
Number of subjects: 90
Study: 1928974

Group type: EXPERIMENTAL
Intervention: Inhaled SK&F 104353 (average nebulized dose, 893 micrograms)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 6
Study: 6126285

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study: 31596129

Group type: EXPERIMENTAL
Intervention: Targeted training group
Number of subjects: 230

Group type: COMPARATOR
Intervention: Non-targeted training group
Number of subjects: 230
Study: 28679182

Group type: EXPERIMENTAL
Intervention: Dapoxetine (Group A)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Group Psychotherapy (Group B)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Dapoxetine and Group Psychotherapy (Group C)
Number of subjects: 157
Study: 25328091

Group type: EXPERIMENTAL
Intervention: Metformin powder formulation
Number of subjects: 602

Group type: COMPARATOR
Intervention: Metformin tablets formulation
Number of subjects: 602
Study: 23882107

Group type: EXPERIMENTAL
Intervention: Controlled breathing techniques
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 22563177

Group type: EXPERIMENTAL
Intervention: Cap-fitted colonoscopy (CFC)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Non-cap-fitted colonoscopy (NCF)
Number of subjects: 295
Study: 19152203

Group type: EXPERIMENTAL
Intervention: Methadone doses >= 60 mg/day
Number of subjects: 2831

Group type: EXPERIMENTAL
Intervention: Flexible dosing strategies
Number of subjects: 2831
Study: 18545119

Group type: EXPERIMENTAL
Intervention: Femoral nerve blockade
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intravenous metamizole
Number of subjects: 52
Study: 15790607

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Depot GnRH analogue
Number of subjects: 82
Study: 12006728

Group type: EXPERIMENTAL
Intervention: Complementary treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 10223255

Group type: EXPERIMENTAL
Intervention: Awareness of Memory Impairment Scale (AMIS)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Difference scores and clinical ratings
Number of subjects: 203